Administration Intravesical BCG Vaccine/*adverse effects/*therapeutic use Humans Meta-Analysis as Topic Randomized Controlled Trials as Topic *Systematic Reviews as Topic Urinary Bladder Neoplasms/*drug therapy

Carcinogenesis/genetics/*immunology/pathology *Genetic Predisposition to Disease Humans Inflammation/genetics/*immunology/pathology *Polymorphism Single Nucleotide Receptors Interleukin/*genetics Urinary Bladder Neoplasms/genetics/*immunology/pathology Bladder urothelial carcinoma Gene polymorphism Interleukin 17 Interleukin 23 Interleukin-23 receptor Natural killers Tumour-associated macrophages

Cystoscopy/*methods Feasibility Studies Humans Liquid Biopsy/methods Sensitivity and Specificity *Spectrum Analysis Raman Urinary Bladder/diagnostic imaging/*pathology Urinary Bladder Neoplasms/*diagnosis/pathology/urine Urine/cytology Bladder cancer Raman spectroscopy diagnosis meta-analysis optical

Disease-Free Survival *Dose Fractionation Radiation Humans Neoplasm Recurrence Local/epidemiology/pathology/*radiotherapy Radiation Dose Hypofractionation/*standards Risk Factors Treatment Outcome Urinary Bladder Neoplasms/epidemiology/pathology/*radiotherapy

Carcinoma Transitional Cell/mortality/surgery Cystectomy Disease-Free Survival Humans Nephroureterectomy Prognosis *Sex Factors Urinary Bladder Neoplasms/*mortality/*surgery Urologic Neoplasms/*mortality/*surgery carcinoma meta-analysis review [publication type] transitional cell urinary bladder neoplasms

Administration Intravesical Antineoplastic Agents/*administration & dosage/adverse effects Clinical Trials as Topic Disease Progression Humans Neoplasm Metastasis *Neoplasm Recurrence Local Network Meta-Analysis Progression-Free Survival Risk Assessment Risk Factors Time Factors Urinary Bladder Neoplasms/*drug therapy/mortality/pathology

*Clinical Protocols *Cystectomy/methods *Enhanced Recovery After Surgery Humans Time Factors Treatment Outcome Urinary Bladder Neoplasms/*surgery Cystectomy Eras Fast track Meta-analysis Protocol Systematic review evidence-based medicine

Bladder cancer complications cystectomy frailty mortality organisation regarding the material discussed in the manuscript.

external thermal field thermotherapy hyperthermic intravesical chemotherapy meta-analysis non-muscle invasive bladder cancer normal temperature intravesical chemotherapy thermal intravesical chemotherapy

Carcinoma Transitional Cell/*classification/*genetics/mortality Humans Predictive Value of Tests Survival Rate Treatment Outcome Urinary Bladder Neoplasms/*classification/*genetics/mortality Bladder cancer Molecular classification Molecular subtype Prognosis Progression Urothelial carcinoma

Humans Lymphocytes/*pathology Neutrophils/*pathology *Preoperative Care Prognosis Publication Bias Survival Analysis Urinary Bladder Neoplasms/*immunology/*surgery

Biomarkers Tumor/*analysis Carcinoma Transitional Cell/*chemistry/*drug therapy Humans Neoadjuvant Therapy Prognosis Urinary Bladder Neoplasms/*chemistry/*drug therapy Biomarkers Nac Neoadjuvant systemic therapy Ucb bladder cancer systematic review

Endoscopic bladder cancer follow-up surveillance form (available at http://dx.doi.org/10.21037/tau-20-1363). The series “Expectant Management in Genitourinary Malignancies (Prostate Bladder Kidney)” was commissioned by the editorial office without any funding or sponsorship. The authors have no other conflicts of interest to declare.

Animals Diabetes Mellitus/*physiopathology Disease Progression Humans Obesity/*complications Urinary Bladder Neoplasms/etiology/*pathology all-cause mortality cancer specific mortality diabetes disease recurrence obesity overweight urinary bladder cancer commercial or financial relationships that could be construed as a potential conflict of interest.

Quality of life (QoL) bladder cancer non-muscle invasive bladder cancer (NMIBC) surveillance form (available at http://dx.doi.org/10.21037/tau-20-1333). The series “Expectant Management in Genitourinary Malignancies (Prostate Bladder Kidney)” was commissioned by the editorial office without any funding or sponsorship. The authors have no other conflicts of interest to declare.

Carcinoma Transitional Cell/*drug therapy Humans Prognosis Receptors Fibroblast Growth Factor/*antagonists & inhibitors Urinary Bladder Neoplasms/*drug therapy Bladder cancer Fgfr FGFR inhibitors Fgfr3 Progression Urothelial carcinoma

Carcinoma in Situ/*diagnosis/*therapy Humans Treatment Outcome Urinary Bladder Neoplasms/*diagnosis/*therapy Bladder cancer Carcinoma in situ Non–muscle-invasive bladder cancer

Cystectomy/adverse effects/*methods Disease-Free Survival Follow-Up Studies Humans Incidence Intraoperative Complications/*epidemiology/etiology Length of Stay/statistics & numerical data Neoplasm Recurrence Local/*epidemiology/etiology/prevention & control Randomized Controlled Trials as Topic Urinary Bladder/*injuries/pathology/surgery Urinary Bladder Neoplasms/mortality/pathology/*surgery Bipolar bladder tumors meta-analysis monopolar transurethral resection

Adjuvants Immunologic/*administration & dosage Administration Intravesical BCG Vaccine/*administration & dosage Humans *Lymphocytes Tumor-Infiltrating Treatment Outcome Urinary Bladder Neoplasms/*drug therapy/immunology/*pathology

Urinary bladder neoplasms adjuvant chemotherapy meta-analysis neoadjuvant chemotherapy (NAC) form (available at http://dx.doi.org/10.21037/tau-20-571). Dr. XZ serves as an unpaid editorial board member of Translational Andrology and Urology from Mar 2015 to Feb 2021. The other authors have no conflicts of interest to declare.